News headlines about Zafgen (NASDAQ:ZFGN) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zafgen earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.6795802973044 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the news headlines that may have effected Accern’s scoring:

ZFGN has been the subject of a number of research reports. ValuEngine raised shares of Zafgen from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 6th. Zacks Investment Research cut shares of Zafgen from a “buy” rating to a “hold” rating in a research note on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $6.38.

Zafgen (NASDAQ:ZFGN) traded up 2.39% during mid-day trading on Friday, hitting $3.43. 45,203 shares of the stock were exchanged. Zafgen has a one year low of $2.89 and a one year high of $5.46. The company has a 50-day moving average price of $3.46 and a 200-day moving average price of $3.90. The company’s market cap is $94.27 million.

Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. During the same quarter last year, the firm posted ($0.55) earnings per share. Analysts forecast that Zafgen will post ($2.23) earnings per share for the current fiscal year.

In related news, insider Dennis D. Kim acquired 10,000 shares of Zafgen stock in a transaction that occurred on Tuesday, July 11th. The stock was purchased at an average price of $3.39 per share, for a total transaction of $33,900.00. Following the completion of the purchase, the insider now directly owns 21,443 shares of the company’s stock, valued at $72,691.77. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 21.20% of the stock is owned by company insiders.

WARNING: “Zafgen (ZFGN) Earns Daily News Sentiment Score of 0.11” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Insider Buying and Selling by Quarter for Zafgen (NASDAQ:ZFGN)

Receive News & Stock Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related stocks with our FREE daily email newsletter.